About GRIP MOLECULAR TECHNOLOGIES INC
GRIP Molecular Technologies develops next-generation CRISPR-based diagnostic platforms that deliver molecular-grade performance with the simplicity of lateral flow assays, enabling fast, accurate, and affordable point-of-care testing for infectious diseases.
CRISPR protease-powered molecular testingRapid results in minutes at room temperatureNo nucleic acid amplification requiredAdaptable to multiple readout formats (lateral flow, electrochemical, colorimetric)Pathogen and sample agnostic (detects bacteria, viruses, fungi; works with saliva, swabs, urine)Plug-and-play manufacturing integration with immunoassay pipelines
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| Federal contract award | Department of Health and Human Services | $354K |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to GRIP MOLECULAR TECHNOLOGIES INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.